StockWireNews
Could This Low Float Nasdaq Biopharma Be Breakout Bound Near Term After Recent FDA News?
Full Report Arrives At 8:00PM EST Tonight
Sign Up To My SMS Update System - Directions Below
March 13th
Greetings Readers,
Did you see what my (3/7/23) Nasdaq profile (NMTC) did?
If not, it's okay. To make up for it, I've got a new breakout idea for Tuesday AM. But more on that in a sec...
NMTC put together an impressive 3-day surge from an open of $1.61 to a high of $2.07 on (3/9/23).
That's a short term blast of approximately 28%.
Solid stuff. But it's time to turn up the heat.
At 8:00PM EST tonight, I'm delivering a complete report on a Nasdaq Biopharma company that just had a game-changing PR this week.
And if it's as important as I think it is, it may just be a matter of time until it starts garnering Wall Street's attention.
So before they catch wind, it may be the perfect time to get it on our radars.
Cool? Cool.
To get you prepared for this upcoming report, I've compiled a small list of potential catalysts that could lend a breakout spark near term.
Check them out:
New Nasdaq Biopharma Profile - 3 Must-Know Potential Breakout Catalysts
#1. As I mentioned above, this profile had a recent FDA ruling that could be monumental moving forward.
With this news continuing to spread, this Nasdaq idea could become a breakout target this coming week.
#2. Huge market potential. Research indicates that the specific market this company could disrupt is growing at an impressive rate, and could reach over $17Bn by the end of the year.
Even more research believes the market could reach $23+Bn by 2027.
#3. A low float! With very few shares available for trading, volatility needs to be on watch on a daily basis.
Since there's time, help yourself:
